510(k) device
Atellica® IM High-Sensitivity Troponin I (TnIH)
Siemens Healthcare Diagnostics, Inc. · Immunoassay Method, Troponin Subunit (MMI, Class II) · First FDA decision Jul 19, 2018, newest Jul 25, 2024Heart attack (myocardial infarction)Heart attack and heart failure blood tests
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
0
Naming "Atellica IM High-Sensitivity"
MAUDE reports
652
Brand "Atellica IM High-Sensitivity", since 2015
PubMed studies
8
Mentioning "Atellica IM High-Sensitivity"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Atellica® IM High-Sensitivity Troponin I (TnIH)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K241165 · Decided Jul 25, 2024 · 90 days after receipt
Device type: Immunoassay Method, Troponin Subunit (MMI) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Atellica IM High-Sensitivity", any status and sponsor, newest update first.
No registered device study names "Atellica IM High-Sensitivity".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Atellica IM High-Sensitivity", and for the whole product code for context.
This brand
652 reports: 652 malfunction, 0 injury, 0 death
Whole product code MMI
7,546 reports: 7,009 malfunction, 528 injury, 4 death
Newest reports for this brand
Siemens Healthcare Diagnostics, Inc.
1219913-2026-00202 · Received Oct 30, 2026 · Event dated Oct 27, 2026
Device type: Immunoassay Method, Troponin Subunit (MMI)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Atellica IM High-Sensitivity"[tiab]. The summary above synthesizes these.
- Analytical verification and comparative assessment of the new Atellica IM high-sensitivity prostate specific antigen assay.
Filella X, González-Escribano C, Rodríguez-García M, et al. · Clin Chem Lab Med · 2026Comparative Study
- Analytical performance comparing siemens whole blood point of care Atellica VTLi to the central laboratory plasma Atellica IM high-sensitivity cardiac troponin I assays.
Xiong-Hang K, Schulz K, Sandoval Y, et al. · Clin Biochem · 2023
- Performance evaluation of the high sensitive troponin I assay on the Atellica IM analyser.
Buño Soto A, Peoc'h K, Fasano T, et al. · Biochem Med (Zagreb) · 2022
- Clinical derivation and data simulated validation of rule-out and rule-in algorithms for the Siemens Atellica IM high-sensitivity cardiac troponin I assay.
Restan IZ, Steiro OT, Pickering JW, et al. · Eur Heart J Acute Cardiovasc Care · 2025Multicenter Study, Validation Study
- Troponin Request Indications and Subsequent Cardiac Management in Acute Care: A Retrospective Quality Improvement Project.
Gogna AC, Harrison H, Yiu D · Cureus · 2026
- Rapid Rule-Out of Myocardial Infarction Using a Single High-Sensitivity Cardiac Troponin I Measurement Strategy at Presentation to the Emergency Department: The SAFETY Study.
Fabre-Estremera B, Smith SW, Sandoval Y, et al. · Clin Chem · 2023Observational Study, Research Support, Non-U.S. Gov't
- External validation of a rapid algorithm using high-sensitivity troponin assay results for evaluating patients with suspected acute myocardial infarction.
Cullen L, Greenslade JH, Stephensen L, et al. · Emerg Med J · 2024Observational Study, Multicenter Study
- Effect of Outlier Elimination on the 99th Percentile Upper Reference Limits of High-Sensitivity Cardiac Troponin I Assays Based on a Strictly Selected Healthy Reference Population.
Ahn S, Kim HK, Lee W, et al. · Ann Lab Med · 2022
Other devices of this type
Also filed under product code MMI.
- Access hsTnIBeckman Coulter, Inc. · 510(k) 2025
- Elecsys Troponin T Gen 5Roche Diagnostics · 510(k) 2021
- i-STAT hs-TnI cartridge with the i-STAT Alinity SystemAbbott Point of Care, Inc. · 510(k) 2026
- VITROS Immunodiagnostic Products hs Troponin I Reagent PackOrtho-Clinical Diagnostics, Inc. · 510(k) 2025
- Alinity i STAT High Sensitivity Troponin-IAbbott Laboratories Diagnostics Division · 510(k) 2023
- Vidas Troponin I Ultra (Tniu) Assay, Model 30 448bioMerieux, Inc. · 510(k) 2007
- Dimension Vista Ctni Flex Reagent CartridgeDade Behring, Inc. · 510(k) 2007
- Abbott Axsym Troponin-I AdvAbbott Laboratories · 510(k) 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.